Clareo Health | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed Grade 1, 2, or 3a FL or nodal MZL, splenic MZL, or extra nodal MZL
Willingness to avoid pregnancy or fathering children
In the opinion of the investigator, be able and willing to receive adequate mandatory prophylaxis and/or therapy for thromboembolic events (eg, aspirin 70-325 mg daily or low-molecular-weight heparin)
Previously treated with at least 1 prior systemic anti-CD20 immunotherapy or chemo-immunotherapy
Documented relapsed, refractory, or PD after treatment with systemic therapy
ECOG performance status of 0 to 2
You may not be if
Women who are pregnant or breastfeeding.
Any histology other than FL and MZL or clinical evidence of transformed lymphoma
Prior non-hematologic malignancy
Congestive heart failure
HCV positivity, chronic HBV infection or history of HIV infection
Active systemic infection
CNS lymphoma involvement
Any systemic anti-lymphoma and/or investigational therapy within 28 days prior to the start of Cycle 1
Prior use of lenalidomide in combination with rituximab
